Neurizon Therapeutics Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neur… Read more
Neurizon Therapeutics Ltd - Asset Resilience Ratio
Neurizon Therapeutics Ltd (NUZ) has an Asset Resilience Ratio of 0.46% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Neurizon Therapeutics Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Neurizon Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$20.00K | 0.46% |
| Total Liquid Assets | AU$20.00K | 0.46% |
Asset Resilience Insights
- Limited Liquidity: Neurizon Therapeutics Ltd maintains only 0.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Neurizon Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Neurizon Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Neurizon Therapeutics Ltd (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Neurizon Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.46% | AU$20.00K | AU$4.36 Million | +0.42pp |
| 2024-06-30 | 0.04% | AU$4.22K | AU$11.12 Million | -0.03pp |
| 2023-06-30 | 0.07% | AU$4.22K | AU$6.13 Million | 0.00pp |
| 2022-06-30 | 0.07% | AU$4.22K | AU$6.13 Million | +0.03pp |
| 2021-06-30 | 0.04% | AU$4.22K | AU$10.08 Million | +0.00pp |
| 2020-06-30 | 0.04% | AU$4.22K | AU$10.95 Million | 0.00pp |
| 2019-06-30 | 0.04% | AU$4.29K | AU$10.75 Million | -0.01pp |
| 2018-06-30 | 0.05% | AU$4.29K | AU$8.60 Million | -0.03pp |
| 2017-06-30 | 0.08% | AU$6.27K | AU$8.36 Million | +0.02pp |
| 2016-06-30 | 0.05% | AU$4.29K | AU$8.20 Million | -0.02pp |
| 2015-06-30 | 0.07% | AU$4.29K | AU$6.26 Million | -0.02pp |
| 2014-06-30 | 0.09% | AU$8.57K | AU$9.52 Million | -0.01pp |
| 2013-06-30 | 0.10% | AU$8.57K | AU$8.21 Million | +0.02pp |
| 2012-06-30 | 0.09% | AU$2.05K | AU$2.41 Million | -0.36pp |
| 2011-06-30 | 0.44% | AU$6.40K | AU$1.45 Million | -0.18pp |
| 2010-06-30 | 0.62% | AU$9.00K | AU$1.45 Million | -1.30pp |
| 2009-06-30 | 1.93% | AU$131.45K | AU$6.83 Million | +0.89pp |
| 2008-06-30 | 1.04% | AU$78.45K | AU$7.57 Million | -- |